Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of cardiovascular (CV) risk biomarkers in participants with type 2 diabetes or obesity without diabetes
Authors' conclusion
Orforglipron treatment was associated with beneficial changes in CV risk markers in participants with T2D and in participants with overweight/obesity without T2D.
Study context
- Population
- Participants with available samples from phase 2 trials: T2D (N = 361; mean age 59 years, 40% female, mean HbA1c 8.1%, mean BMI 35.3 kg/m²) or overweight/obesity without DM (N = 234; mean age 54 years, 60% female, mean BMI 37.9 kg/m²)T2D N = 361
- Comparison
- Once-daily oral orforglipron vs placebo
- Primary endpoint
- Change from baseline in BP, lipids (cholesterol, TG, ApoB, ApoC3), NT-pro-BNP and inflammatory biomarkers (hsCRP, IL-6)
- Follow-up
- 26 weeks (T2D study) or 36 weeks (obesity study)
Primary result
As reported in the abstract
CV risk markers · 26 weeks (T2D) / 36 weeks (obesity)
- Significant placebo-adjusted decreases from baseline in BP, low-density lipoprotein (LDL) cholesterol, TG, Apolipoprotein B (ApoB), Apolipoprotein C3 (ApoC3) and high-sensitivity C-reactive protein (hsCRP) with orforglipron in T2D and/or overweight or obesity
- In both studies, improvements in BP, lipids and most biomarkers of similar magnitude with orforglipron 12 mg as with 24, 36 and 45 mg
- Exploratory analysis
Original publication
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. Published 6 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →